# A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors

> **NCT00721669** · PHASE1 · COMPLETED · sponsor: **ImmunoGen, Inc.** · enrollment: 60 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** IMGN388

## Key facts

- **NCT ID:** NCT00721669
- **Lead sponsor:** ImmunoGen, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2012-10
- **Final completion:** 2012-12
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2013-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00721669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00721669, "A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00721669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*